Since the discovery 15 years ago in 2007 (9), and the development of high-impact targeted ALK-inhibitor (ALKi) therapy, treatment and survival have been revolutionized for patients living with ALK-rearranged NSCLC (10). This evidence concerns the gene ALK and non-small cell lung carcinoma.